Sign up to save your podcasts
Or
Share FDA Approval of Zanidatamab - HERIZON-BTC-01 Discussion with Dr. Shubham Pant
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Approval of Zanidatamab - HERIZON-BTC-01 Discussion with Dr. Shubham Pant
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer.
Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting.
Key topics include:
• Overview of biliary tract cancer and its treatment landscape
• Study design and patient characteristics from the HERIZON-BTC-01 trial
• Key findings, including overall response rates and duration of response
• The importance of HER2 testing and its implications for treatment sequencing
• Side effect profiles and management strategies for Zanidatamab
• Future directions and ongoing clinical trials
Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer.
Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer.
Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting.
Key topics include:
• Overview of biliary tract cancer and its treatment landscape
• Study design and patient characteristics from the HERIZON-BTC-01 trial
• Key findings, including overall response rates and duration of response
• The importance of HER2 testing and its implications for treatment sequencing
• Side effect profiles and management strategies for Zanidatamab
• Future directions and ongoing clinical trials
Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer.
Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
321 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
502 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
360 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners